Immunobiology of HPV and HPV vaccines

Gynecologic Oncology

Volumn 109, Issue 2 SUPPL., 2008, Pages

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibodies; HPV; Immunity; Interferons; Vaccines; VLP

Indexed keywords

ALUMINUM HYDROXIDE; HEPATITIS B VACCINE; INTERFERON; PHOSPHORYL LIPID A; PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL MIGRATION; DENDRITIC CELL; DISEASE ASSOCIATION; DNA REPLICATION; DOWN REGULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; PROTEIN EXPRESSION; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS;

ALPHAPAPILLOMAVIRUS; ANIMALS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 43049163972     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.02.003     Document Type: Article

References (50)

1. Jablonska S., Dabrowski J., and Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res 32 (1972) 583-589
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
3. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
4. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25
5. Doorbar J. The papillomavirus life cycle. J Clin Virol 32 Suppl 1 (2005) S7-S15
6. Middleton K., Peh W., Southern S., Griffin H., Sotlar K., Nakahara T., et al. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77 (2003) 10186-10201
7. Munger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78 (2004) 1160-11451
8. Stanley M. Immune responses to human papillomavirus. Vaccine 24 Suppl 1 (2006) S16-S22
9. Fausch S.C., Da Silva D.M., Rudolf M.P., and Kast W.M. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 169 (2002) 3242-3249
10. Da Silva D.M., Fausch S.C., Verbeek J.S., and Kast W.M. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fc{gamma} receptors and contributes to acquisition of T cell immunity. J Immunol 178 (2007) 7587-7597
11. Le Bon A., and Tough D.F. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14 (2002) 432-436
12. Kanodia S., Fahey L.M., and Kast W.M. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 7 (2007) 79-89
13. Chang Y.E., and Laimins L.A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74 (2000) 4174-4182
14. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., and Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75 (2001) 4283-4296
15. Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., et al. Immunological events in regressing genital warts. Am J Clin Pathol 102 (1994) 768-774
16. de Jong A., van der Burg S.H., Kwappenberg K.M.C., van der Hulst J.M., Franken K.L.M.C., Geluk A., et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62 (2002) 472-479
17. Welters M.J., de Jong A., van den Eeden S.J., van der Hulst J.M., Kwappenberg K.M., Hassane S., et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63 (2003) 636-641
18. Nicholls P.K., Moore P.F., Anderson D.M., Moore R.A., Parry N.R., Gough G.W., et al. Regression of canine oral papillomas is associated with infiltration of CD4+and CD8+lymphocytes. Virology 283 (2001) 31-39
19. Nicholls P.K., Klaunberg B.A., Moore R.A., Santos E.B., Parry N.R., Gough G.W., et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 265 (1999) 365-374
20. Carter J.J., Wipf G.C., Hagensee M.E., McKnight B., Habel L.A., Lee S.K., et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 172 (1995) 11-18
21. Carter J.J., Koutsky L.A., Wipf G.C., Christensen N.D., Lee S.K., Kuypers J., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 (1996) 927-936
22. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 9 (1999) 423-430
23. Pett M., and Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. J Pathol 212 4 (2007) 356-367
24. Herdman M.T., Pett M.R., Roberts I., Alazawi W.O., Teschendorff A.E., Zhang X.Y., et al. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27 (2006) 2341-2353
25. Pett M.R., Herdman M.T., Palmer R.D., Yeo G.S., Shivji M.K., Stanley M.A., et al. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A 103 (2006) 3822-3827
26. de Jong A., van Poelgeest M.I., van der Hulst J.M., Drijfhout J.W., Fleuren G.J., Melief C.J., et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+T-cell immunity against early antigens E2 and E6. Cancer Res 64 (2004) 5449-5455
27. Kobayashi A., Greenblatt R.M., Anastos K., Minkoff H., Massad L.S., Young M., et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 64 (2004) 6766-6774
28. Shope R.E. Immunization of rabbits to infectious papillomatosis. J Exp Med 65 (1937) 607-624
29. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
30. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
31. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93 (2001) 284-492
32. Yang R., Murillo F.M., Cui H., Blosser R., Uematsu S., Takeda K., et al. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78 (2004) 11152-11160
33. Yan M., Peng J., Jabbar I.A., Liu X., Filgueira L., Frazer I.H., et al. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol 83 (2005) 83-91
34. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 370 9596 (2007) 1414
35. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
36. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
37. Koutsky L.A., and Harper D.M. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 24 Suppl 3 (2006) S114-S121
38. TM. Abstract presented at the 2008 annual meeting of the Society of Gynecologic Oncologists.
39. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 (1995) 3959-3963
40. Ghim S., Newsome J., Jenson A.B., Schlegel R., Suzich J., Tamura J., et al. Formalin-inactivated oral papilloma extracts and recombinant L1 vaccines protect completely against mucosal papillomavirus infection: a canine model. Vaccines 95 (1995), Laboratory Press, Cold Spring Harbor 375-379
41. Ghim S., Newsome J., Bell J., Sundberg J.P., Schlegel R., and Jenson A.B. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 68 (2000) 147-151
42. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13 7 (2007) 857-861
43. Stanley M.A., Moore R.A., Nicholls P.K., Santos E.B., Thomsen L., Parry N., et al. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19 (2001) 2783-2792
44. Christensen N.D., Reed C.A., Cladel N.M., Han R., and Kreider J.W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70 (1996) 960-965
45. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24 (2006) 5571-5583
46. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
47. Olsson S.E., Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Malm C., et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25 (2007) 4931-4939
48. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil ((R)) cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3 (2007)
49. Li H., Nookala S., and Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178 (2007) 5271-5276
50. Caulfield M.J., Shi L., Wang S., Wang B., Tobery T.W., Mach H., et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum Vaccin 3 (2007)